Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,841,364
  • Shares Outstanding, K 146,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,340 K
  • EBIT $ -352 M
  • EBITDA $ -352 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.22

Options Overview Details

View History
  • Implied Volatility 56.00% ( -3.37%)
  • Historical Volatility 41.59%
  • IV Percentile 9%
  • IV Rank 37.54%
  • IV High 113.03% on 11/24/23
  • IV Low 21.73% on 08/23/24
  • Put/Call Vol Ratio 0.33
  • Today's Volume 265
  • Volume Avg (30-Day) 620
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 40,833
  • Open Int (30-Day) 39,073

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.71
  • Number of Estimates 10
  • High Estimate -0.56
  • Low Estimate -0.80
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -97.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.61 +8.17%
on 11/19/24
32.10 -17.07%
on 11/06/24
-2.75 (-9.36%)
since 10/21/24
3-Month
24.61 +8.17%
on 11/19/24
34.47 -22.77%
on 09/06/24
-5.84 (-17.99%)
since 08/21/24
52-Week
24.61 +8.17%
on 11/19/24
45.58 -41.60%
on 01/09/24
-6.34 (-19.24%)
since 11/21/23

Most Recent Stories

More News
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

IMVT : 26.49 (+1.22%)
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

IMVT : 26.49 (+1.22%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

AMGN : 290.19 (+0.81%)
ARGX : 589.23 (-0.44%)
BGNE : 193.30 (-0.49%)
CRSP : 46.33 (-1.97%)
IMVT : 26.49 (+1.22%)
Why Immunovant Stock Is Bolting Higher Today

The company may have best-in-class autoimmune disease therapy under its roof.

ARGX : 589.23 (-0.44%)
JNJ : 155.69 (+1.69%)
IMVT : 26.49 (+1.22%)
ROIV : 11.83 (+2.96%)
Stocks Tumble as Confidence in the U.S. Economic Outlook Wanes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -1.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,956.24 (+0.66%)
SPY : 594.65 (+0.70%)
$DOWI : 43,968.19 (+1.29%)
DIA : 439.88 (+1.29%)
$IUXX : 20,751.68 (+0.41%)
QQQ : 505.72 (+0.51%)
CTAS : 221.27 (+1.15%)
AMZN : 197.76 (-2.52%)
AAPL : 229.27 (+0.12%)
GOOGL : 166.52 (-5.38%)
MSFT : 413.45 (-0.29%)
META : 562.15 (-0.60%)
Why Shares of Immunovant Are Soaring on Tuesday

Immunovant sees strong potential for an autoimmune disorder therapy.

ROIV : 11.83 (+2.96%)
RJF : 164.34 (+1.33%)
IMVT : 26.49 (+1.22%)
Stocks Retreat on U.S. Economic Concerns

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -1.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.78%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.07%....

$SPX : 5,956.24 (+0.66%)
SPY : 594.65 (+0.70%)
$DOWI : 43,968.19 (+1.29%)
DIA : 439.88 (+1.29%)
$IUXX : 20,751.68 (+0.41%)
QQQ : 505.72 (+0.51%)
CTAS : 221.27 (+1.15%)
AMZN : 197.76 (-2.52%)
GOOGL : 166.52 (-5.38%)
AAPL : 229.27 (+0.12%)
MSFT : 413.45 (-0.29%)
META : 562.15 (-0.60%)
These 2 Biotech Stocks Are Bucking a Down Market Tuesday

Stock index futures pointed to a lower open on Wall Street Tuesday morning.

IMVT : 26.49 (+1.22%)
ROIV : 11.83 (+2.96%)
Markets Today: Stocks Slip on Additional Hawkish Fed Comments

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.41%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.44%. Stock index futures this morning are moderately lower. Stock markets...

ESZ24 : 5,978.50 (+0.69%)
NQZ24 : 20,831.50 (+0.40%)
TSLA : 342.04 (unch)
UNFI : 23.57 (+3.20%)
THO : 111.40 (+2.87%)
OLN : 41.84 (+2.52%)
COTY : 7.18 (+0.56%)
FLS : 60.26 (+0.62%)
EW : 70.65 (+1.60%)
DKNG : 44.15 (+0.80%)
IMVT : 26.49 (+1.22%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

IMVT : 26.49 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 27.99
2nd Resistance Point 27.10
1st Resistance Point 26.64
Last Price 26.49
1st Support Level 25.29
2nd Support Level 24.40
3rd Support Level 23.94

See More

52-Week High 45.58
Fibonacci 61.8% 37.57
Fibonacci 50% 35.10
Fibonacci 38.2% 32.62
Last Price 26.49
52-Week Low 24.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar